<DOC>
	<DOC>NCT02436486</DOC>
	<brief_summary>To evaluate the effect of idalopirdine (120 and 360 mg) on cardiac repolarisation in healthy men.</brief_summary>
	<brief_title>Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men</brief_title>
	<detailed_description />
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Body weight at least 50 kg and Body Mass index &gt;18.5 and &lt; 30 kg/m2 Good general health ascertained by a detailed medical history, laboratory tests and physical examination Use of contraception. The subject has evidence of cardiac conduction abnormalities as calculated by the ECG equipment and evaluated by the investigator, at the Screening Visit or at the Baseline visit The subject has a history of long QT syndrome, history of cardiac arrhythmia, or history of cardiac disease (eg, coronary artery disease, valvular disease, etc.). Other protocol defined inclusion and exclusion criteria do apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>